Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells
Chelation therapy is a known effective method to increase the excretion of U(VI) from the body. Until now, no any uranium chelator has been approved for emergency medical use worldwide. The present study aimed to evaluate the efficacy of new ligand BPCBG containing two catechol groups and two aminoc...
Gespeichert in:
Veröffentlicht in: | Toxicology and applied pharmacology 2013-05, Vol.269 (1), p.17-24 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 24 |
---|---|
container_issue | 1 |
container_start_page | 17 |
container_title | Toxicology and applied pharmacology |
container_volume | 269 |
creator | Bao, Yizhong Wang, Dan Li, Zhiming Hu, Yuxing Xu, Aihong Wang, Quanrui Shao, Chunlin Chen, Honghong |
description | Chelation therapy is a known effective method to increase the excretion of U(VI) from the body. Until now, no any uranium chelator has been approved for emergency medical use worldwide. The present study aimed to evaluate the efficacy of new ligand BPCBG containing two catechol groups and two aminocarboxylic acid groups in decorporation of U(VI) and protection against acute U(VI) nephrotoxicity in rats, and further explored the detoxification mechanism of BPCBG for U(VI)-induced nephrotoxicity in HK-2 cells with comparison to DTPA-CaNa3. Chelating agents were administered at various times before or after injections of U(VI) in rats. The U(VI) levels in urine, kidneys and femurs were measured 24h after U(VI) injections. Histopathological changes in the kidney and serum urea and creatinine and urine protein were examined. After treatment of U(VI)-exposed HK-2 cells with chelating agent, the intracellular U(VI) contents, formation of micronuclei, lactate dehydrogenase (LDH) activity and production of reactive oxygen species (ROS) were assessed. It was found that prompt, advanced or delayed injections of BPCBG effectively increased 24h-urinary U(VI) excretion and decreased the levels of U(VI) in kidney and bone. Meanwhile, BPCBG injection obviously reduced the severity of the U(VI)-induced histological alterations in the kidney, which was in parallel with the amelioration noted in serum indicators, urea and creatinine, and urine protein of U(VI) nephrotoxicity. In U(VI)-exposed HK-2 cells, immediate and delayed treatment with BPCBG significantly decreased the formation of micronuclei and LDH release by inhibiting the cellular U(VI) intake, promoting the intracellular U(VI) release and inhibiting the production of intracellular ROS. Our data suggest that BPCBG is a novel bi-functional U(VI) decorporation agent with a better efficacy than DTPA-CaNa3.
► BPCBG accelerated the urine U(VI) excretion and reduced the tissues U(VI) in rats. ► BPCBG can effectively protect against the U(VI)-induced nephrotoxicity in rats. ► BPCBG increased the U(VI) release and reduced the U(VI) uptake in HK-2 cells. ► BPCBG decreased the U(VI)-induced MN formation and LDH release in HK-2 cells. ► BPCBG eliminated the U(VI)-induced intracellular ROS in HK-2 cells. |
doi_str_mv | 10.1016/j.taap.2013.02.010 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22285292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041008X1300080X</els_id><sourcerecordid>23454449</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-26448bc2913225c43c969eaf551c02dae930e2c095f17a5585944b535b7b9fa83</originalsourceid><addsrcrecordid>eNp9kM9u1DAQhy1ERZeWF-CALKEeE8b_dmOJC12VFlGpHKjEzZo49tarxFnZ2ZX6BLw2TreFGyePPN9vNPMR8p5BzYAtP23rCXFXc2CiBl4Dg1dkwUAvKxBCvCYLAMkqgObXKXmb8xYAtJTsDTnlQioppV6Q31feB4v2kY6eIo3jwfXUPrgepzHRyx_ry2vqS5XcMB5C3NB9whj2A8XY0V0aJ2en-Rs3GGKeXtpViN3euq7kIpaBru9phwNuHA2RJpzy04Cb7xV_auZzcuKxz-7d83tG7r9e_VzfVLd319_WX24rK5mcKr6Usmkt10xwrqwUVi-1Q68Us8A7dFqA4xa08myFSjWqXNwqodpVqz024ox8PM4d8xRMtqEc8GDHGMsdhnPeKK55ofiRsmnMOTlvdikMmB4NAzO7N1szuzezewPcFPcl9OEY2u3bwXV_Iy-yC3DxDGC22Puiyob8j1sJ1cBKFe7zkXNFxCG4NO_pYtEZ0rxmN4b_7fEHKPahhQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Bao, Yizhong ; Wang, Dan ; Li, Zhiming ; Hu, Yuxing ; Xu, Aihong ; Wang, Quanrui ; Shao, Chunlin ; Chen, Honghong</creator><creatorcontrib>Bao, Yizhong ; Wang, Dan ; Li, Zhiming ; Hu, Yuxing ; Xu, Aihong ; Wang, Quanrui ; Shao, Chunlin ; Chen, Honghong</creatorcontrib><description>Chelation therapy is a known effective method to increase the excretion of U(VI) from the body. Until now, no any uranium chelator has been approved for emergency medical use worldwide. The present study aimed to evaluate the efficacy of new ligand BPCBG containing two catechol groups and two aminocarboxylic acid groups in decorporation of U(VI) and protection against acute U(VI) nephrotoxicity in rats, and further explored the detoxification mechanism of BPCBG for U(VI)-induced nephrotoxicity in HK-2 cells with comparison to DTPA-CaNa3. Chelating agents were administered at various times before or after injections of U(VI) in rats. The U(VI) levels in urine, kidneys and femurs were measured 24h after U(VI) injections. Histopathological changes in the kidney and serum urea and creatinine and urine protein were examined. After treatment of U(VI)-exposed HK-2 cells with chelating agent, the intracellular U(VI) contents, formation of micronuclei, lactate dehydrogenase (LDH) activity and production of reactive oxygen species (ROS) were assessed. It was found that prompt, advanced or delayed injections of BPCBG effectively increased 24h-urinary U(VI) excretion and decreased the levels of U(VI) in kidney and bone. Meanwhile, BPCBG injection obviously reduced the severity of the U(VI)-induced histological alterations in the kidney, which was in parallel with the amelioration noted in serum indicators, urea and creatinine, and urine protein of U(VI) nephrotoxicity. In U(VI)-exposed HK-2 cells, immediate and delayed treatment with BPCBG significantly decreased the formation of micronuclei and LDH release by inhibiting the cellular U(VI) intake, promoting the intracellular U(VI) release and inhibiting the production of intracellular ROS. Our data suggest that BPCBG is a novel bi-functional U(VI) decorporation agent with a better efficacy than DTPA-CaNa3.
► BPCBG accelerated the urine U(VI) excretion and reduced the tissues U(VI) in rats. ► BPCBG can effectively protect against the U(VI)-induced nephrotoxicity in rats. ► BPCBG increased the U(VI) release and reduced the U(VI) uptake in HK-2 cells. ► BPCBG decreased the U(VI)-induced MN formation and LDH release in HK-2 cells. ► BPCBG eliminated the U(VI)-induced intracellular ROS in HK-2 cells.</description><identifier>ISSN: 0041-008X</identifier><identifier>EISSN: 1096-0333</identifier><identifier>DOI: 10.1016/j.taap.2013.02.010</identifier><identifier>PMID: 23454449</identifier><identifier>CODEN: TXAPA9</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; Animals ; Biological and medical sciences ; Biological effects of radiation ; Biomarkers - blood ; Body Burden ; Cell Line ; Chelating agents ; Chelating Agents - administration & dosage ; Chelating Agents - pharmacology ; Chelation Therapy - methods ; CREATININE ; Creatinine - blood ; Cytoprotection ; DEPLETED URANIUM ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; DTPA ; EXCRETION ; Fundamental and applied biological sciences. Psychology ; Glycine - administration & dosage ; Glycine - analogs & derivatives ; Glycine - pharmacology ; HK-2 cell line ; Humans ; INJECTION ; Injections ; Ionizing radiations ; Kidney Diseases - blood ; Kidney Diseases - chemically induced ; Kidney Diseases - pathology ; Kidney Diseases - prevention & control ; Kidney Tubules - drug effects ; Kidney Tubules - metabolism ; Kidney Tubules - pathology ; KIDNEYS ; L-Lactate Dehydrogenase - metabolism ; LACTATE DEHYDROGENASE ; Male ; Mechanism ; Medical sciences ; Micronuclei, Chromosome-Defective - chemically induced ; Micronuclei, Chromosome-Defective - drug effects ; Organometallic Compounds ; Pentetic Acid - pharmacology ; RATS ; Rats, Sprague-Dawley ; Reactive Oxygen Species - metabolism ; Time Factors ; Tissues, organs and organisms biophysics ; Toxicology ; Uranium decorporation ; Urea - blood ; URINE</subject><ispartof>Toxicology and applied pharmacology, 2013-05, Vol.269 (1), p.17-24</ispartof><rights>2013 Elsevier Inc.</rights><rights>2014 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-26448bc2913225c43c969eaf551c02dae930e2c095f17a5585944b535b7b9fa83</citedby><cites>FETCH-LOGICAL-c414t-26448bc2913225c43c969eaf551c02dae930e2c095f17a5585944b535b7b9fa83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0041008X1300080X$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27358075$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23454449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22285292$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Bao, Yizhong</creatorcontrib><creatorcontrib>Wang, Dan</creatorcontrib><creatorcontrib>Li, Zhiming</creatorcontrib><creatorcontrib>Hu, Yuxing</creatorcontrib><creatorcontrib>Xu, Aihong</creatorcontrib><creatorcontrib>Wang, Quanrui</creatorcontrib><creatorcontrib>Shao, Chunlin</creatorcontrib><creatorcontrib>Chen, Honghong</creatorcontrib><title>Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells</title><title>Toxicology and applied pharmacology</title><addtitle>Toxicol Appl Pharmacol</addtitle><description>Chelation therapy is a known effective method to increase the excretion of U(VI) from the body. Until now, no any uranium chelator has been approved for emergency medical use worldwide. The present study aimed to evaluate the efficacy of new ligand BPCBG containing two catechol groups and two aminocarboxylic acid groups in decorporation of U(VI) and protection against acute U(VI) nephrotoxicity in rats, and further explored the detoxification mechanism of BPCBG for U(VI)-induced nephrotoxicity in HK-2 cells with comparison to DTPA-CaNa3. Chelating agents were administered at various times before or after injections of U(VI) in rats. The U(VI) levels in urine, kidneys and femurs were measured 24h after U(VI) injections. Histopathological changes in the kidney and serum urea and creatinine and urine protein were examined. After treatment of U(VI)-exposed HK-2 cells with chelating agent, the intracellular U(VI) contents, formation of micronuclei, lactate dehydrogenase (LDH) activity and production of reactive oxygen species (ROS) were assessed. It was found that prompt, advanced or delayed injections of BPCBG effectively increased 24h-urinary U(VI) excretion and decreased the levels of U(VI) in kidney and bone. Meanwhile, BPCBG injection obviously reduced the severity of the U(VI)-induced histological alterations in the kidney, which was in parallel with the amelioration noted in serum indicators, urea and creatinine, and urine protein of U(VI) nephrotoxicity. In U(VI)-exposed HK-2 cells, immediate and delayed treatment with BPCBG significantly decreased the formation of micronuclei and LDH release by inhibiting the cellular U(VI) intake, promoting the intracellular U(VI) release and inhibiting the production of intracellular ROS. Our data suggest that BPCBG is a novel bi-functional U(VI) decorporation agent with a better efficacy than DTPA-CaNa3.
► BPCBG accelerated the urine U(VI) excretion and reduced the tissues U(VI) in rats. ► BPCBG can effectively protect against the U(VI)-induced nephrotoxicity in rats. ► BPCBG increased the U(VI) release and reduced the U(VI) uptake in HK-2 cells. ► BPCBG decreased the U(VI)-induced MN formation and LDH release in HK-2 cells. ► BPCBG eliminated the U(VI)-induced intracellular ROS in HK-2 cells.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Biological effects of radiation</subject><subject>Biomarkers - blood</subject><subject>Body Burden</subject><subject>Cell Line</subject><subject>Chelating agents</subject><subject>Chelating Agents - administration & dosage</subject><subject>Chelating Agents - pharmacology</subject><subject>Chelation Therapy - methods</subject><subject>CREATININE</subject><subject>Creatinine - blood</subject><subject>Cytoprotection</subject><subject>DEPLETED URANIUM</subject><subject>Dose-Response Relationship, Drug</subject><subject>Drug Administration Schedule</subject><subject>DTPA</subject><subject>EXCRETION</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Glycine - administration & dosage</subject><subject>Glycine - analogs & derivatives</subject><subject>Glycine - pharmacology</subject><subject>HK-2 cell line</subject><subject>Humans</subject><subject>INJECTION</subject><subject>Injections</subject><subject>Ionizing radiations</subject><subject>Kidney Diseases - blood</subject><subject>Kidney Diseases - chemically induced</subject><subject>Kidney Diseases - pathology</subject><subject>Kidney Diseases - prevention & control</subject><subject>Kidney Tubules - drug effects</subject><subject>Kidney Tubules - metabolism</subject><subject>Kidney Tubules - pathology</subject><subject>KIDNEYS</subject><subject>L-Lactate Dehydrogenase - metabolism</subject><subject>LACTATE DEHYDROGENASE</subject><subject>Male</subject><subject>Mechanism</subject><subject>Medical sciences</subject><subject>Micronuclei, Chromosome-Defective - chemically induced</subject><subject>Micronuclei, Chromosome-Defective - drug effects</subject><subject>Organometallic Compounds</subject><subject>Pentetic Acid - pharmacology</subject><subject>RATS</subject><subject>Rats, Sprague-Dawley</subject><subject>Reactive Oxygen Species - metabolism</subject><subject>Time Factors</subject><subject>Tissues, organs and organisms biophysics</subject><subject>Toxicology</subject><subject>Uranium decorporation</subject><subject>Urea - blood</subject><subject>URINE</subject><issn>0041-008X</issn><issn>1096-0333</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM9u1DAQhy1ERZeWF-CALKEeE8b_dmOJC12VFlGpHKjEzZo49tarxFnZ2ZX6BLw2TreFGyePPN9vNPMR8p5BzYAtP23rCXFXc2CiBl4Dg1dkwUAvKxBCvCYLAMkqgObXKXmb8xYAtJTsDTnlQioppV6Q31feB4v2kY6eIo3jwfXUPrgepzHRyx_ry2vqS5XcMB5C3NB9whj2A8XY0V0aJ2en-Rs3GGKeXtpViN3euq7kIpaBru9phwNuHA2RJpzy04Cb7xV_auZzcuKxz-7d83tG7r9e_VzfVLd319_WX24rK5mcKr6Usmkt10xwrqwUVi-1Q68Us8A7dFqA4xa08myFSjWqXNwqodpVqz024ox8PM4d8xRMtqEc8GDHGMsdhnPeKK55ofiRsmnMOTlvdikMmB4NAzO7N1szuzezewPcFPcl9OEY2u3bwXV_Iy-yC3DxDGC22Puiyob8j1sJ1cBKFe7zkXNFxCG4NO_pYtEZ0rxmN4b_7fEHKPahhQ</recordid><startdate>20130515</startdate><enddate>20130515</enddate><creator>Bao, Yizhong</creator><creator>Wang, Dan</creator><creator>Li, Zhiming</creator><creator>Hu, Yuxing</creator><creator>Xu, Aihong</creator><creator>Wang, Quanrui</creator><creator>Shao, Chunlin</creator><creator>Chen, Honghong</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>OTOTI</scope></search><sort><creationdate>20130515</creationdate><title>Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells</title><author>Bao, Yizhong ; Wang, Dan ; Li, Zhiming ; Hu, Yuxing ; Xu, Aihong ; Wang, Quanrui ; Shao, Chunlin ; Chen, Honghong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-26448bc2913225c43c969eaf551c02dae930e2c095f17a5585944b535b7b9fa83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Biological effects of radiation</topic><topic>Biomarkers - blood</topic><topic>Body Burden</topic><topic>Cell Line</topic><topic>Chelating agents</topic><topic>Chelating Agents - administration & dosage</topic><topic>Chelating Agents - pharmacology</topic><topic>Chelation Therapy - methods</topic><topic>CREATININE</topic><topic>Creatinine - blood</topic><topic>Cytoprotection</topic><topic>DEPLETED URANIUM</topic><topic>Dose-Response Relationship, Drug</topic><topic>Drug Administration Schedule</topic><topic>DTPA</topic><topic>EXCRETION</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Glycine - administration & dosage</topic><topic>Glycine - analogs & derivatives</topic><topic>Glycine - pharmacology</topic><topic>HK-2 cell line</topic><topic>Humans</topic><topic>INJECTION</topic><topic>Injections</topic><topic>Ionizing radiations</topic><topic>Kidney Diseases - blood</topic><topic>Kidney Diseases - chemically induced</topic><topic>Kidney Diseases - pathology</topic><topic>Kidney Diseases - prevention & control</topic><topic>Kidney Tubules - drug effects</topic><topic>Kidney Tubules - metabolism</topic><topic>Kidney Tubules - pathology</topic><topic>KIDNEYS</topic><topic>L-Lactate Dehydrogenase - metabolism</topic><topic>LACTATE DEHYDROGENASE</topic><topic>Male</topic><topic>Mechanism</topic><topic>Medical sciences</topic><topic>Micronuclei, Chromosome-Defective - chemically induced</topic><topic>Micronuclei, Chromosome-Defective - drug effects</topic><topic>Organometallic Compounds</topic><topic>Pentetic Acid - pharmacology</topic><topic>RATS</topic><topic>Rats, Sprague-Dawley</topic><topic>Reactive Oxygen Species - metabolism</topic><topic>Time Factors</topic><topic>Tissues, organs and organisms biophysics</topic><topic>Toxicology</topic><topic>Uranium decorporation</topic><topic>Urea - blood</topic><topic>URINE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bao, Yizhong</creatorcontrib><creatorcontrib>Wang, Dan</creatorcontrib><creatorcontrib>Li, Zhiming</creatorcontrib><creatorcontrib>Hu, Yuxing</creatorcontrib><creatorcontrib>Xu, Aihong</creatorcontrib><creatorcontrib>Wang, Quanrui</creatorcontrib><creatorcontrib>Shao, Chunlin</creatorcontrib><creatorcontrib>Chen, Honghong</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>OSTI.GOV</collection><jtitle>Toxicology and applied pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bao, Yizhong</au><au>Wang, Dan</au><au>Li, Zhiming</au><au>Hu, Yuxing</au><au>Xu, Aihong</au><au>Wang, Quanrui</au><au>Shao, Chunlin</au><au>Chen, Honghong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells</atitle><jtitle>Toxicology and applied pharmacology</jtitle><addtitle>Toxicol Appl Pharmacol</addtitle><date>2013-05-15</date><risdate>2013</risdate><volume>269</volume><issue>1</issue><spage>17</spage><epage>24</epage><pages>17-24</pages><issn>0041-008X</issn><eissn>1096-0333</eissn><coden>TXAPA9</coden><abstract>Chelation therapy is a known effective method to increase the excretion of U(VI) from the body. Until now, no any uranium chelator has been approved for emergency medical use worldwide. The present study aimed to evaluate the efficacy of new ligand BPCBG containing two catechol groups and two aminocarboxylic acid groups in decorporation of U(VI) and protection against acute U(VI) nephrotoxicity in rats, and further explored the detoxification mechanism of BPCBG for U(VI)-induced nephrotoxicity in HK-2 cells with comparison to DTPA-CaNa3. Chelating agents were administered at various times before or after injections of U(VI) in rats. The U(VI) levels in urine, kidneys and femurs were measured 24h after U(VI) injections. Histopathological changes in the kidney and serum urea and creatinine and urine protein were examined. After treatment of U(VI)-exposed HK-2 cells with chelating agent, the intracellular U(VI) contents, formation of micronuclei, lactate dehydrogenase (LDH) activity and production of reactive oxygen species (ROS) were assessed. It was found that prompt, advanced or delayed injections of BPCBG effectively increased 24h-urinary U(VI) excretion and decreased the levels of U(VI) in kidney and bone. Meanwhile, BPCBG injection obviously reduced the severity of the U(VI)-induced histological alterations in the kidney, which was in parallel with the amelioration noted in serum indicators, urea and creatinine, and urine protein of U(VI) nephrotoxicity. In U(VI)-exposed HK-2 cells, immediate and delayed treatment with BPCBG significantly decreased the formation of micronuclei and LDH release by inhibiting the cellular U(VI) intake, promoting the intracellular U(VI) release and inhibiting the production of intracellular ROS. Our data suggest that BPCBG is a novel bi-functional U(VI) decorporation agent with a better efficacy than DTPA-CaNa3.
► BPCBG accelerated the urine U(VI) excretion and reduced the tissues U(VI) in rats. ► BPCBG can effectively protect against the U(VI)-induced nephrotoxicity in rats. ► BPCBG increased the U(VI) release and reduced the U(VI) uptake in HK-2 cells. ► BPCBG decreased the U(VI)-induced MN formation and LDH release in HK-2 cells. ► BPCBG eliminated the U(VI)-induced intracellular ROS in HK-2 cells.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>23454449</pmid><doi>10.1016/j.taap.2013.02.010</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-008X |
ispartof | Toxicology and applied pharmacology, 2013-05, Vol.269 (1), p.17-24 |
issn | 0041-008X 1096-0333 |
language | eng |
recordid | cdi_osti_scitechconnect_22285292 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | 60 APPLIED LIFE SCIENCES Animals Biological and medical sciences Biological effects of radiation Biomarkers - blood Body Burden Cell Line Chelating agents Chelating Agents - administration & dosage Chelating Agents - pharmacology Chelation Therapy - methods CREATININE Creatinine - blood Cytoprotection DEPLETED URANIUM Dose-Response Relationship, Drug Drug Administration Schedule DTPA EXCRETION Fundamental and applied biological sciences. Psychology Glycine - administration & dosage Glycine - analogs & derivatives Glycine - pharmacology HK-2 cell line Humans INJECTION Injections Ionizing radiations Kidney Diseases - blood Kidney Diseases - chemically induced Kidney Diseases - pathology Kidney Diseases - prevention & control Kidney Tubules - drug effects Kidney Tubules - metabolism Kidney Tubules - pathology KIDNEYS L-Lactate Dehydrogenase - metabolism LACTATE DEHYDROGENASE Male Mechanism Medical sciences Micronuclei, Chromosome-Defective - chemically induced Micronuclei, Chromosome-Defective - drug effects Organometallic Compounds Pentetic Acid - pharmacology RATS Rats, Sprague-Dawley Reactive Oxygen Species - metabolism Time Factors Tissues, organs and organisms biophysics Toxicology Uranium decorporation Urea - blood URINE |
title | Efficacy of a novel chelator BPCBG for removing uranium and protecting against uranium-induced renal cell damage in rats and HK-2 cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A28%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20a%20novel%20chelator%20BPCBG%20for%20removing%20uranium%20and%20protecting%20against%20uranium-induced%20renal%20cell%20damage%20in%20rats%20and%20HK-2%20cells&rft.jtitle=Toxicology%20and%20applied%20pharmacology&rft.au=Bao,%20Yizhong&rft.date=2013-05-15&rft.volume=269&rft.issue=1&rft.spage=17&rft.epage=24&rft.pages=17-24&rft.issn=0041-008X&rft.eissn=1096-0333&rft.coden=TXAPA9&rft_id=info:doi/10.1016/j.taap.2013.02.010&rft_dat=%3Cpubmed_osti_%3E23454449%3C/pubmed_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/23454449&rft_els_id=S0041008X1300080X&rfr_iscdi=true |